Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Skeletal muscle loss as an adverse event during Cabozantinib treatment in patients with metastatic renal cell carcinoma

Date

30 Sep 2019

Session

Poster Display session 3

Presenters

Carolina Alves Costa Silva

Citation

Annals of Oncology (2019) 30 (suppl_5): v356-v402. 10.1093/annonc/mdz249

Authors

C. Alves Costa Silva1, D. AFONSO2, E. Colomba1, G. Le Teuff3, L. Derosa4, B. Raynard5, A. Guida6, A. Benchimol-Zouari2, B. Escudier7, F. BIDAULT2, L. Albiges8

Author affiliations

  • 1 Medical Oncology Department, Gustave Roussy, 94805 - Villejuif/FR
  • 2 Radiology, Gustave Roussy Institute, 94800 - Villejuif/FR
  • 3 Biostatistics And Epidemiology, Gustave Roussy, Villejuif/FR
  • 4 Medical Oncology Department, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 5 Dietetics And Nutrition Department, Supportive Care Department, Gustave Roussy, 94805 - Villejuif/FR
  • 6 Medical Onology, Azienda Ospedaliero - Universitaria Policlinico di Modena, 41125 - Modena/IT
  • 7 Medical Oncology, Gustave Roussy - Cancer Campus, 94805 - Villejuif/FR
  • 8 Medical Oncology, Institut Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Background

Cabozantinib (CABO) is currently a standard of care as 2nd or 3rd line in metastatic renal cell carcinoma (mRCC). Previous studies showed that sarcopenia is generally linked with worse survival and/or higher toxicity in oncology. The aim is to evaluate its impact in mRCC patients (pt) treated with CABO.

Methods

Unicentric study of consecutive pt treated with CABO for mRCC from January 2014 to December 2018 and with available computed tomography images (CT). CT were centrally reviewed and axial L3 sections were used to measure the total muscle area and calculate skeletal muscle index (SMI, cm²/m²). Sarcopenia was defined as SMI lower than a sex-based threshold. Sarcopenic event-free survival was estimated from CABO start. Treatment-related toxicity (TRT), defined as dose reduction and/or treatment stop, was evaluated.

Results

Overall, 95 pts with median-follow-up of 15.4 months (mo) from CABO start were included. The median age was 61 (range 28-75) years, 71 (74.7%) pts had clear cell histology. IMDC group distribution: 11.7% good, 62.8% intermediate and 25.5% poor. CABO was administered in 1rd (3.2%), 2nd (30.5%), 3rd line (26.3%) and beyond (40.0%). At CABO start, median BMI was 24.7kg/m², median SMI was 46.6 with 61 (64.2%) sarcopenic pt. For non-sarcopenic pt at baseline (n = 34), 18 (52.9%) developed sarcopenia during treatment with a median sarcopenic event-free survival of 6.7 mo (95%CI 3.5-27.4). Overall, 79 (83.2%) pt experienced muscle mass loss during the treatment: the relative variation of muscle loss between baseline and worst value was ≤5% in 22.1%, ]5-10%] in 26.3%, ]10-20%] in 24.2% and >20% in 10.5%. The best response was CR (1.1%), PR (35.5%), SD (54.8%) and PD (8.6%). Median time-to-TRT was 2.5 mo (95%CI 2.1-3.3; 74.7% events) and median overall survival was 20.1 mo (95%CI 18.0-NE; 35.8% deaths). Both endpoints were not associated to sarcopenia at CABO start.

Conclusions

We reported the first cohort assessing sarcopenia in pt treated with CABO for mRCC. Baseline sarcopenia is underestimated in this setting. Furthermore, half of non-sarcopenic patients at baseline develop sarcopenia during treatment requiring physician awareness and interventional studies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Onco-urology department of Gustave Roussy.

Disclosure

E. Colomba: Travel / Accommodation / Expenses: BMS; Travel / Accommodation / Expenses: Ipsen; Travel / Accommodation / Expenses: PFIZER; Travel / Accommodation / Expenses: SANOFI. B. Escudier: Honoraria (self), Advisory / Consultancy: Pfizer; Honoraria (self), Advisory / Consultancy: BMS; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Ipsen; Honoraria (self), Advisory / Consultancy: Roche; Honoraria (self), Advisory / Consultancy: Oncorena. L. Albiges: Honoraria (institution), Advisory / Consultancy: Novartis; Honoraria (institution), Advisory / Consultancy: Bristol‐Myers Squibb; Honoraria (institution), Advisory / Consultancy: Merck; Honoraria (institution), Advisory / Consultancy: Roche; Honoraria (institution), Advisory / Consultancy: Pfizer; Honoraria (institution), Advisory / Consultancy: Amgen; Honoraria (institution), Advisory / Consultancy: Ipsen; Honoraria (institution), Advisory / Consultancy: Astellas Pharma. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings